tiprankstipranks
CV Sciences Inc (CVSI)
OTHER OTC:CVSI
Want to see CVSI full AI Analyst Report?

CV Sciences (CVSI) Price & Analysis

502 Followers

CVSI Stock Chart & Stats

$0.09
>-$0.01(-7.69%)
At close: 4:00 PM EST
$0.09
>-$0.01(-7.69%)

Bulls Say, Bears Say

Bulls Say
High Gross MarginsSustainably high gross margins imply product economics can absorb SG&A and pricing pressure. With margins elevated versus peers and continued insourcing to lower COGS, the company has durable unit-level profitability that can support break-even once fixed costs shrink and volumes stabilize.
Cost Reductions And Cash-flow ProgressMeaningful SG&A cuts and operating improvements reduced losses and produced early positive operating cash flow. These persistent cost disciplines and the debt-to-convertible restructuring increase financial flexibility, improving the odds management reaches sustained cash-flow breakeven in H2 2026.
Brand Strength And Channel DiversificationA leading hemp-extract brand and a large direct-to-consumer mix give pricing control, higher margins, and customer data for repeatability. New non‑cannabinoid SKUs broaden the addressable market, reducing category concentration risk and supporting durable revenue mix diversification over the medium term.
Bears Say
Declining Revenue And Unit SalesSustained top-line erosion signals structural category contraction and loss of volume scale. Continued unit declines hinder fixed-cost absorption, slow margin recovery, and make it harder to convert improved unit economics into durable profitability absent share gains or new high-growth product anchors.
Negative Cash Flow And Tight LiquidityPersistent negative operating and free cash flow with very low absolute cash creates financing vulnerability. Even modest execution setbacks could force dilutive financings or constrain marketing and inventory investments, limiting the company's ability to scale new SKUs and realize synergies.
Regulatory Uncertainty Over Product EligibilityAmbiguous federal rules and appropriations-driven constraints can require reformulation, restrict distribution channels, or delay payer adoption. These structural regulatory risks raise compliance costs, slow market expansion (including CMS BEI adoption), and could permanently shrink the addressable consumer base.

CV Sciences News

CVSI FAQ

What was CV Sciences Inc’s price range in the past 12 months?
CV Sciences Inc lowest stock price was $0.01 and its highest was $0.10 in the past 12 months.
    What is CV Sciences Inc’s market cap?
    CV Sciences Inc’s market cap is $4.90M.
      When is CV Sciences Inc’s upcoming earnings report date?
      CV Sciences Inc’s upcoming earnings report date is Aug 17, 2026 which is in 44 days.
        How were CV Sciences Inc’s earnings last quarter?
        CV Sciences Inc released its earnings results on May 14, 2026. The company reported -$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.003.
          Is CV Sciences Inc overvalued?
          According to Wall Street analysts CV Sciences Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does CV Sciences Inc pay dividends?
            CV Sciences Inc does not currently pay dividends.
            What is CV Sciences Inc’s EPS estimate?
            CV Sciences Inc’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does CV Sciences Inc have?
            CV Sciences Inc has 203,977,520 shares outstanding.
              What happened to CV Sciences Inc’s price movement after its last earnings report?
              CV Sciences Inc reported an EPS of -$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.448%.
                Which hedge fund is a major shareholder of CV Sciences Inc?
                Currently, no hedge funds are holding shares in CVSI
                What is the TipRanks Smart Score and how is it calculated?
                Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                  Company Description

                  CV Sciences Inc

                  CV Sciences, Inc. functions as a life sciences organization primarily operating across North America. Its business activities are organized into two distinct divisions: Consumer Products and Specialty Pharmaceutical. The Consumer Products division focuses on the creation, manufacturing, and commercialization of plant-derived dietary supplements and cannabidiol (CBD) products sourced from hemp. These offerings are marketed under various brand identities including PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet. They serve a wide array of health and wellness sectors such as nutraceuticals, personal care, specialty food items, and pet products. The company distributes these goods through its own digital platforms, other online retailers, a network of chosen distributors, and traditional brick-and-mortar stores. In contrast, the Specialty Pharmaceutical division is dedicated to the research, advancement, and eventual market launch of cannabinoids for the treatment of specific medical conditions. A key project in this segment involves the drug candidate CVSI-007, an innovative combination of CBD and nicotine designed to combat smokeless tobacco use and dependence. Established in 2010, the company was initially known as CannaVest Corp. before officially adopting the name CV Sciences, Inc. in January 2016. Its main corporate offices are located in San Diego, California.

                  CV Sciences (CVSI) Earnings & Revenues

                  CVSI Earnings Call

                  Q1 2026
                  0:00 / 0:00
                  Earnings Call Sentiment|Positive
                  The call highlights meaningful operational progress: year-over-year margin expansion, a ~13% reduction in operating expenses, improved adjusted EBITDA (loss narrowed to $0.1M), and a notable shift to positive operating cash flow. Management is actively diversifying into non-cannabinoid health products, launching new SKUs, insourcing manufacturing, and integrating recent acquisitions to realize synergies in H2 2026. However, revenue trends remain a concern (down 11% YoY, unit sales down ~12%), GAAP net loss widened to $0.6M, cash on hand is low (~$0.3M), and regulatory uncertainty persists and could require product changes. On balance, the operational and financial improvements and strategic initiatives provide a constructive trajectory toward profitability and cash flow breakeven, outweighing the top-line and regulatory challenges in the near term.View all CVSI earnings summaries
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  cbdMD
                  Cosmos Holdings
                  IM Cannabis Corp
                  Incannex Healthcare Limited Sponsored ADR

                  Ownership Overview

                  <0.01%100.00%
                  Insiders
                  Mutual Funds
                  <0.01% Other Institutional Investors
                  100.00% Public Companies and
                  Individual Investors

                  Options Prices

                  Currently, No data available
                  ---
                  Popular Stocks